Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: ProQR is a clinical-stage biotechnology company focused on developing RNA editing therapeutics using its proprietary Axiomer platform. The company has shifted its strategy exclusively to this platform, divesting its legacy ophthalmology assets (sepofarsen and ultevursen) to Laboratoires Théa in December 2023. Current pipeline focus includes AX-0810 (cholestatic diseases), AX-2402 (Rett syndrome), and AX-2911 (MASH).
Key Financial Metrics
| Metric (€ thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | 15,906 | 18,905 |
| Net Loss | (42,184) | (27,763) |
| Research & Development Costs | (44,733) | (36,356) |
| General & Administrative Costs | (15,060) | (13,661) |
| Cash and Cash Equivalents (Year End) | 92,413 | 149,408 |
| Accumulated Deficit | (467,506) | (427,158) |
| Outstanding Ordinary Shares | 105,361,064 | 105,361,064 |
Note: The filing text does not provide specific margin percentages or debt-to-equity ratios. The company has no product revenue; revenue is derived from collaboration agreements and grants.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss widened by €14.4 million (52% increase) to €42.2 million, driven primarily by higher R&D expenses.
- Revenue Decline: Revenue decreased by €3.0 million (16%) to €15.9 million. This was due to fewer milestones achieved under the Eli Lilly collaboration in 2025 (€3.9 million) compared to 2024 (€5.1 million).
- R&D Expense Growth: R&D costs increased by €8.4 million (23%) to €44.7 million, attributed to higher outsourced activities for the Lilly collaboration and increased investment in internal pipeline targets (AX-0810, AX-2402).
- Cash Burn: Net cash used in operating activities increased to €52.8 million in 2025 from €36.4 million in 2024. Total cash and cash equivalents decreased by €57.0 million year-over-year.
- Financing Activity: Unlike 2024, which saw significant equity raises (€71.6 million net proceeds), 2025 had no equity issuances. Financing activities resulted in a net cash outflow of €1.8 million, primarily due to lease liability repayments.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management estimates that existing cash and cash equivalents (€92.4 million) are sufficient to fund anticipated operations into mid-2027. The company expects to continue incurring significant losses as it advances its Axiomer platform and clinical programs.
Key Pipeline Updates:
- AX-0810: Phase 1 clinical trial in healthy volunteers commenced in December 2025. Preliminary safety data from the first cohort (3 mg/kg) reported in January 2026 showed no serious adverse events.
- AX-2402: Development candidate announced in early 2026; first-in-human trial expected in H1 2027. Supported by an expanded partnership with the Rett Syndrome Research Trust (RSRT) totaling $9.2 million.
- AX-2911: Development candidate announced in early 2026 for MASH targeting PNPLA3.
Material Risks and Contingencies:
- Capital Needs: The company requires additional capital to fund operations. Failure to obtain financing could force delays or discontinuation of development programs.
- Regulatory Uncertainty: The RNA editing platform is unproven in humans. Regulatory approval processes are lengthy and unpredictable.
- Collaboration Dependence: Significant revenue and future milestones depend on the success of the Eli Lilly collaboration and the RSRT partnership.
- Intellectual Property: The company faces patent oppositions in Australia and Europe regarding its Axiomer platform patents.
- Geopolitical and Economic Factors: Risks include potential tariffs, supply chain disruptions, and the impact of U.S. healthcare policy changes (e.g., MFN pricing proposals) on future reimbursement.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2027" liquidity estimate against current monthly burn rates and potential acceleration of clinical spending.
- Lilly Collaboration Milestones: Review the specific criteria for future milestone payments under the Eli Lilly agreement to assess revenue visibility.
- AX-0810 Clinical Data: Monitor the release of biomarker data from the healthy volunteer cohort expected in H1 2026 to validate target engagement.
- Patent Status: Track the outcome of ongoing patent oppositions in Europe and Australia regarding the Axiomer platform.
- RSRT Funding: Confirm the receipt and utilization of the expanded $8.2 million funding from the Rett Syndrome Research Trust.